Rayburn West Financial Services LLC Buys Shares of 47,530 Pfizer Inc. $PFE

Key Points

• Rayburn West Financial Services initiated a new position in Pfizer, buying 47,530 shares valued at about $1.18 million in the fourth quarter.
• Pfizer reported Q1 earnings and revenue above expectations, with EPS of $0.75 versus $0.72 expected and revenue of $14.45 billion, up 5.4% year over year.
• The company also declared a quarterly dividend of $0.43 per share, implying an annualized yield of about 6.6%, while analysts currently rate the stock a consensus "Hold" with an average price target of $28.74.

Rayburn West Financial Services LLC bought a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 47,530 shares of the biopharmaceutical company's stock, valued at approximately $1,183,000.

Other hedge funds have also added to or reduced their stakes in the company. Horizon Financial Services LLC raised its holdings in shares of Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 645 shares in the last quarter. YANKCOM Partnership purchased a new stake in shares of Pfizer in the 4th quarter valued at about $28,000. Grey Fox Wealth Advisors LLC purchased a new stake in shares of Pfizer in the 3rd quarter valued at about $29,000. Darwin Wealth Management LLC purchased a new stake in shares of Pfizer in the 2nd quarter valued at about $32,000. Finally, Torren Management LLC purchased a new stake in shares of Pfizer in the 4th quarter valued at about $34,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of NYSE PFE opened at $25.96 on Thursday. The stock has a market cap of $147.93 billion, a price-to-earnings ratio of 19.81 and a beta of 0.35. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a 1-year low of $21.97 and a 1-year high of $28.75. The stock's 50-day moving average is $27.03 and its 200 day moving average is $26.19.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to analysts' expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.Pfizer's revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period last year, the firm posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer's payout ratio is 131.30%.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer won European Commission approval to expand HYMPAVZI (marstacimab) for hemophilia A and B patients with inhibitors, a label expansion that could help broaden future sales. European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors
• Positive Sentiment: Analyst coverage highlighted Pfizer’s rebound story, with the company targeting high-single-digit revenue CAGR from 2029 as new launches, acquisitions, and pipeline growth may offset patent-expiration headwinds. Can Pfizer Achieve High Single-Digit Revenue CAGR From 2029?
• Positive Sentiment: Multiple market commentators argued Pfizer looks undervalued after recent earnings, with some calling it a possible long-term buying opportunity and noting healthy underlying results despite a muted reaction. Top Analyst Reports for Meta, Pfizer & Salesforce
• Neutral Sentiment: Pfizer and partner Arvinas licensed VEPPANU (vepdegestrant) rights to Rigel Pharmaceuticals, bringing Pfizer $85 million in upfront and transition payments plus potential milestones and royalties, but also ceding commercialization control. Pfizer Shifts VEPPANU Rights To Rigel As Valuation Gap Persists
• Negative Sentiment: Bearish commentary continued to focus on Pfizer’s post-pandemic slowdown, with articles questioning dividend sustainability and whether the company can regain stronger growth as older products face loss of exclusivity. Pfizer's Net Income Drops in Q1. Is Its Dividend Still Safe?
• Negative Sentiment: Broader sector coverage also pointed to tougher vaccine demand conditions in the U.S., which could weigh on sentiment toward large pharma names including Pfizer. How tough is it getting for vaccine makers in the U.S.?

Analyst Upgrades and Downgrades

PFE has been the topic of several recent analyst reports. Morgan Stanley raised their price target on Pfizer from $27.00 to $28.00 and gave the company an "equal weight" rating in a report on Friday, April 10th. Daiwa Securities Group cut Pfizer from an "outperform" rating to a "neutral" rating and set a $27.00 price objective on the stock. in a report on Thursday, February 12th. Bank of America decreased their price objective on Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a report on Thursday, April 9th. UBS Group raised their price objective on Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a report on Monday, April 13th. Finally, CICC Research assumed coverage on Pfizer in a report on Thursday, April 16th. They set an "outperform" rating and a $33.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $28.74.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.